Incidence and time course of adverse events (AEs) with atezolizumab (A) in combination with vemurafenib (V) and cobimetinib (C) in the phase III IMspire150 study

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorLewis, K.
dc.contributor.authorRobert, C.
dc.contributor.authorAscierto, P. A.
dc.contributor.authorMunhoz, R.
dc.contributor.authorLiszkay, G.
dc.contributor.authorde la Cruz Merino, L.
dc.contributor.authorOlah, J.
dc.contributor.authorQueirolo, P.
dc.contributor.authorMackiewicz, J.
dc.contributor.authorLi, H.
dc.contributor.authorZhu, Q.
dc.contributor.authorMcKenna, E.
dc.contributor.authorMcNally, V.
dc.contributor.authorGutzmer, R.
dc.contributor.authorMcArthur, G.
dc.contributor.authoraffiliation[Lewis, K.] Univ Colorado, Ctr Comprehens Canc, Med Oncol, Aurora, CO USA
dc.contributor.authoraffiliation[Robert, C.] Gustave Roussy, Dermatol, Villejuif, France
dc.contributor.authoraffiliation[Robert, C.] Univ Paris Saclay, Villejuif, France
dc.contributor.authoraffiliation[Ascierto, P. A.] Ist Nazl Tumori IRCCS Fdn G Pascale, Melanoma Canc Immunotherapy & Dev Therapeut, Naples, Italy
dc.contributor.authoraffiliation[Munhoz, R.] Inst Canc Estado Sao Paulo, Med Oncol, Sao Paulo, Brazil
dc.contributor.authoraffiliation[Munhoz, R.] Orszagos Onkol Int, Med Oncol, Budapest, Hungary
dc.contributor.authoraffiliation[de la Cruz Merino, L.] Hosp Univ Virgen Macarena, Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Olah, J.] Univ Szeged, Szent Gyorgyi Med Univ, Med Oncol, Szeged, Hungary
dc.contributor.authoraffiliation[Queirolo, P.] IRCCS Ist Europeo Oncol, Med Oncol, Milan, Italy
dc.contributor.authoraffiliation[Mackiewicz, J.] Greater Poland Canc Ctr, Dept Diagnost & Canc Immunol, Poznan, Poland
dc.contributor.authoraffiliation[Li, H.] Hoffmanne La Roche Ltd, Med Oncol, Mississauga, ON, Canada
dc.contributor.authoraffiliation[Zhu, Q.] Genentech Inc, Med Oncol, San Francisco, CA 94080 USA
dc.contributor.authoraffiliation[McKenna, E.] Genentech Inc, Med Oncol, San Francisco, CA 94080 USA
dc.contributor.authoraffiliation[McNally, V.] Roche Prod Ltd, Med Oncol, Welwyn Garden City, Herts, England
dc.contributor.authoraffiliation[Gutzmer, R.] Med Hsch Hannover MHH, Klin Dermatol Allergol & Venerol, Haut Tumour Zentrum Hannover HTZH, Med Oncol, Hannover, Germany
dc.contributor.authoraffiliation[McArthur, G.] Peter MacCallum Canc Ctr, Melanoma & Skin Serv, Med Oncol, Melbourne, Australia
dc.contributor.authoraffiliation[McArthur, G.] Peter MacCallum Canc Ctr, Canc Therapeut Program, Melbourne, Australia
dc.contributor.funderF. Hoffmann-La Roche Ltd.
dc.date.accessioned2025-01-07T16:06:02Z
dc.date.available2025-01-07T16:06:02Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.1260
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420412566/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27615
dc.identifier.wosID573469101424
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen Macarena
dc.page.numberS761-S761
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleIncidence and time course of adverse events (AEs) with atezolizumab (A) in combination with vemurafenib (V) and cobimetinib (C) in the phase III IMspire150 study
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen Macarena

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía